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Abstract  Abdominal  obesity  is  associated  with  a  risk  of  cardiovascular  diseases,  metabolic
syndrome  and  decreased  lung  function.  However,  it  is  not  known  whether  asthma  control  is
inﬂuenced  by  the  accumulation  of  adipose  tissue  in  the  various  abdominal  compartments.
Objective: To  determine  associations  among  abdominal  adiposity  distribution,  asthma  control,
lung function  and  cytokines  in  women.
Methods  and  design:  In  this  cross-sectional  study  of  asthmatic  women,  data  on  demographic
variables,  comorbid  conditions,  disease  history,  anthropometric  and  spirometric  measurements
were collected.  Subcutaneous  (SAT)  and  visceral  (VAT)  adipose  tissues  were  measured  by
ultrasound,  and  the  steatosis  level  was  obtained.  Asthma  control  was  assessed  according  to
Global Initiative  for  Asthma  (GINA)  criteria.  Atopy  was  deﬁned  on  the  basis  of  allergen-speciﬁc
Immunoglobulin  E  and/or  skin  prick  testing.  Cytokine  levels  were  determined  using  enzyme-
linked immunosorbant  assays  (ELISAs).
Results:  Eighty-three  asthmatic  women  were  included,  37%  of  whom  had  uncontrolled  asthma.
After controlling  for  variables,  a  negative  association  between  asthma  control  and  VAT  and  the
VAT/SAT ratio  was  observed.  VAT  was  negatively  associated  with  respiratory  parameters  after
controlling  for  explanatory  variables.  In  an  adjusted  model,  body  mass  index  (BMI)  and  SAT
were inversely  associated  with  the  adiponectin  serum  level  and  VAT  was  associated  with  the∗ Corresponding author.
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interleukin  6  level.  In  conclusion,  visceral  obesity  was  negatively  associated  with  asthma  control
and lung  function;  and  positively  associated  with  increased  levels  of  interleukin  6  in  women.  We
hypothesize  that  women  should  be  studied  as  a  separate  group,  and  we  suggest  further  studies
with a  control  group  to  know  if  the  uncontrolled  asthmatic  group  is  directly  affected  by  visceral
adipose inﬂammatory  markers.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an






















































































t  was  recently  reported  that  abdominal  obesity  is  increasing
aster  than  overall  obesity.1 Abdominal  obesity  is  associ-
ted  with  cardiovascular  risk,  metabolic  syndrome2,3 and
ecreased  lung  function.4 However  to  date,  there  is  a
ack  of  correlation  between  obesity  related  inﬂammatory
arkers  and  asthma.5 The  precise  mechanism  and  the  sig-
iﬁcance  of  the  association  between  adipokines,  asthma
nd  visceral  obesity,  considered  to  be  the  most  inﬂamma-
ory  are  unknown.  Most  studies  investigating  the  association
etween  asthma  and  obesity  have  considered  only  body
ass  index.6,7 However,  the  use  of  this  parameter  has  lim-
tations  because  it  does  not  distinguish  between  fat  mass
nd  muscle  or  identify  the  distribution  of  body  fat.8 We
ypothesized  that  the  accumulation  of  abdominal  fat  in  the
isceral  compartment,  which  is  particularly  associated  with
ncreased  inﬂammatory  markers,9,10 could  adversely  affect
ung  function  and  worsen  asthma  control  in  women.  It  is
ossible  that  the  greater  risk  and  morbidity  of  asthma  in
omen11,12 is  in  part  due  to  the  hormonal  changes  that  occur
hroughout  life,13 and  these  changes  may  be  associated
ith  different  forms  of  fat  accumulation,  which  may  inter-
ere  with  asthma  immunoregulation  and  control.  Therefore,
e  aimed  to  evaluate  the  associations  among  ultrasound
easurements  of  abdominal  fat,  serum  concentrations  of
nﬂammatory  cytokines,  asthma  control  and  lung  function
n  women.
aterials and methods
his  cross-sectional  study  was  conducted  in  asthmatic
omen  diagnosed  with  persistent  asthma,  as  deﬁned  by
lobal  Initiative  for  Asthma  (GINA)14 criteria,  using  clini-
al  data  and  lung  function  testing  in  an  outpatient  asthma
linic  at  the  University  Hospital  Gaffrée  and  Guinle  (HUGG)
rom  August  2014  to  January  2015.  The  subjects  were  older
han  17  years  and  were  routinely  followed  up  for  more
han  one  year.  Treatment  with  ﬁxed  doses  based  on  GINA
uidelines14 were  initiated  at  least  three  months  prior  to  the
tudy  by  the  same  physician.  All  the  patients  under  65  years
ld  had  BMI  values  between  18.5  and  39.9  kg/m2 (weight  in
ilograms  divided  by  the  square  of  the  height  in  meters),
hereas  the  BMI  for  those  older  than  65  was  between  22.0
nd  41.9  kg/m2 and  22.0  and  41.9  kg/m2.15 Subjects  were
xcluded  if  they  were  current  smokers  or  had  smoked  within
he  past  5  years,  were  pregnant  or  nursing,  had  a  history
f  psychiatric  diseases,  active  pulmonary  disease,  malig-




Beart  failure,  cardiovascular  disease,  thyroid  dysfunction,
ere  chronic  users  of  systemic  corticosteroids  or  immuno-
uppressive  drugs,  had  previous  use  of  immunotherapy  or
ad  experienced  an  airway  infection  or  exacerbation  during
he  four  weeks  preceding  the  study.
ata  collection
emographic  data  [age  and  education  (less  than  or  more
han  ﬁve  years)],  number  of  parities,  duration  of  disease
less  or  more  than  15  years),  onset  of  disease  (before
r  after  the  age  of  12  years),  onset  after  menopause,
hinitis  symptoms,  use  of  drugs  for  diabetes,  hyperten-
ion  or  gastro-oesophageal  reﬂux  disease  (GERD),  use  of
ystemic  corticosteroids  and  emergency  room  visits  during
he  year  prior  to  the  study,  assessment  of  asthma  severity
nd  control,  anthropometric  measurements  (weight,  height,
aist  circumference),  and  pulmonary  function  parame-
ers  including  pre-bronchodilator  percent-predicted  FEV1
forced  expiratory  volume  in  one  second),  FVC  (forced  vital
apacity)  and  the  FEV1/FVC  ratio  were  obtained.
ssessment  of  asthma  control  and  severity
sthma  control  was  deﬁned  as  fully,  partly  controlled  or
ot  controlled  according  to  the  GINA  guidelines  2012.14 In
ddition,  asthma  severity  was  deﬁned  based  on  the  GINA
002  guidelines,  which  divide  patients  into  4  categories,
ild  intermittent,  mild,  moderate  and  severe  persistent,
ased  on  the  frequency  of  symptoms,  spirometry  results  and
harmacological  treatment.16 Peak  expiratory  ﬂow  (PEF),
xpressed  as  the  percentage  of  the  predicted  value  based
n  age,  sex,  and  height,  was  used  to  assess  asthma  control
nd  severity.17
nthropometric  measures
eight  and  height  were  measured  to  the  nearest  0.1  kg
nd  0.1  cm,  respectively,  according  to  standard  protocols.15
aist  circumference  (WC)  was  measured  to  the  nearest
.1  cm  using  a  nonelastic  tape  measure,  at  the  midpoint
etween  the  lower  costal  margin  and  iliac  crest  at  the  end  of
 normal  expiration  in  supine  position,  with  no  clothes  over
he  site  of  the  measurement  and  with  the  arms  extended
aterally  and  the  feet  together.  All  measurements  were  per-
ormed  by  the  same  physician.  BMI,  waist-to-height  ratio
WHtR)  and  waist-to-hip  ratio  (WHR)  were  calculated.  The



































Eighty-three  women  with  ages  ranging  from  18  to  82  years
old  with  a  mean  age  of  55.39  ±  13.67  years,  were  included.
A  total  of  37.3%  of  women  were  found  to  have  uncon-












tinVisceral  adiposity  is  associated  with  cytokines  and  lung  func
according  to  WHO  (World  Health  Organization)  criteria.  Cen-
tral  obesity  was  deﬁned  according  to  WC,  WHtR  and  WHR
measurements.  The  patients  younger  than  or  older  than
65  years  were  considered  eutrophic  when  their  BMI  val-
ues  were  in  the  ranges  of  18.5--24.9  kg/m2 or  22--27  kg/m2,
overweight  with  BMI  values  in  the  ranges  of  25--29.9  kg/m2
or  27.1--32  kg/m2,  and  obese  with  BMI  values  in  the  ranges
of  30--39.9  kg/m2 or  32.1--41.9  kg/m2.16 Central  obesity  was
deﬁned  as  a  waist  circumference  over  88  cm,  according  to
WHO  criteria,  as  was  a  WHtR  greater  than  0.50  and  a  WHR
greater  than  0.85.15
IgE  and  allergy  skin-prick  testing
Serum  samples  were  analyzed  for  total  and  allergen-speciﬁc
IgE  using  the  Pharmacia  Diagnostics  ImmunoCAP  250  sys-
tem  (Sweden).  The  types  of  allergens  for  which  speciﬁc
IgE  tests  were  performed  included  two  house  dust  mites
(Dermatophagoides  pteronyssinus  and  Blomia  tropicalis)
and  one  fungus  (Aspergillus). A  concentration  of  speciﬁc
IgE  >  0.10  kU/L  was  deﬁned  as  a  positive  test  result.  Aller-
gic  sensitization  to  8  aeroallergens:  three  dust  mites  (D.
pteronyssinus,  D.  farinae  and  B.  tropicalis),  two  fungi
(Alternaria  and  Aspergillus), and  dander  from  three  animals
(cat,  dog  and  cockroach),  was  determined  in  all  subjects
using  skin-prick  tests  according  to  EAACI  (European  Academy
of  Allergology  and  Clinical  Immunology)18 guidelines.  The
skin-prick  test  was  performed  by  Alergolatina  Laboratory
(Rio  de  Janeiro,  Brazil).  Sensitization  was  deﬁned  as  present
with  a  wheal  that  was  greater  than  3  mm  and  greater  than
that  produced  by  the  saline  negative  control.  Atopy  was
deﬁned  by  a  positive  result  for  any  of  the  allergen-speciﬁc
IgEs  and/or  skin-prick  test  for  any  of  the  aeroallergens  listed
above.
Ultrasound  measurements
Ultrasonographic  measurements  were  performed  accord-
ing  to  the  criteria  of  Diniz  et  al.19 by  a  single  physician
using  an  Ultrasound  ACCUVIX-V10.  The  subcutaneous  fat
thickness  was  measured  with  a  7.5  MHz  linear  transducer
transversely  positioned  1  cm  above  the  umbilical  scar.  For
visceral  fat,  a  3.5  MHz  transducer  was  also  positioned  1  cm
above  the  umbilical  scar  and  was  considered  to  be  the
distance  between  the  internal  surface  of  the  abdominal  rec-
tus  muscle  and  the  posterior  aortic  wall  in  the  abdominal
midline.  The  criteria  for  assessing  the  severity  of  hepatic
steatosis  were  those  of  Saadeh  et  al.,20 which  divide  steato-
sis  into  3  categories:  Grades  I  (mild),  II  (moderate),  and  III
(severe).
Assessment  of  respiratory  function
Pulmonary  function  tests  were  performed  according  to
American  Thoracic  Society  (ATS)  guidelines21 by  a single
physician  using  a  Spirometer  Spiron  2  (Codax  Corporation;
São  Paulo,  Brazil)  to  determine  the  pre-bronchodilator-
predicted  FEV1%,  FVC%,  and  FEV1/FVC  ratio.  The  baseline
FEV1 recorded  was  the  best  of  three  reproducible  values
from  acceptable  curves  with  less  than  5%  differences  in
F
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mplitude.  We  used  the  predicted  pulmonary  values  of  the
nudson  standards.22
iochemical  assays
eripheral  blood  was  centrifuged,  and  the  serum  was  divided
nto  200  l aliquots  and  frozen  at  −80 ◦C  prior  to  analy-
is.  Adiponectin,  interleukin  6  (IL-6),  interleukin  8 (IL-8),
ransforming  growth  factor  beta  (TGF-), tumor  necrosis
actor  alpha  (TNF-) and  plasminogen  activator  inhibitor
PAI)  levels  were  determined  using  commercially  available
nzyme-linked  immunosorbant  assay  (ELISA)  kits  (Affymetrix
Bioscience,  San  Diego);  the  detection  sensitivity  levels
ere  10  pg/ml,  2  pg/ml,  2  pg/ml,  8  pg/ml,  4  pg/ml  and
8  pg/ml,  respectively.
tatistical  analysis
ivariate  analyses  were  performed  using  the  t  test  for  con-
inuous  variables  and  the  chi-square  test  for  categorical
ariables  to  investigate  the  relationships  between  clinical
nd  demographic  characteristics  and  asthma  control.  Varia-
les  showing  an  association  with  a  p-value  up  to  0.20  in  the
ivariate  analysis  were  used  in  regression  models.  In  logis-
ic  regression,  a  dichotomous  dependent  variable  was  used
or  asthma  control  (controlled/partly  controlled  versus  not
ontrolled).  The  results  were  expressed  as  odds  ratios  (OR)
nd  95%  conﬁdence  intervals.  For  analyses  of  the  association
f  respiratory  function  parameters,  the  pre-bronchodilator
redicted  FEV1%,  FVC%  and  FEV1/FVC  ratio  were  deﬁned  as
ependent  variables.  Adiponectin  and  IL-6  were  also  used  as
ependent  variables  in  linear  regression  models.  The  level
f  signiﬁcance  was  set  at  5%.  All  analyses  were  performed
sing  SPSS  statistical  software,  version  17.0.  The  study  was
pproved  by  the  Research  Ethics  Committee  of  HUGG  on
une  2014.
esults<50  p >50  p
VAT *
igure  1  Serum  levels  of  adiponectin  according  to  the  50th







Table  1  Linear  regression  model  of  pre-bronchodilator-predicted  FEV1%  in  asthmatic  women;  HUGG,  2014--2015.
FEV1%  predicted
Independent  variable  Category  Model  1aa
  (95%  CI)
Model  2bb
  (95%  CI)
Model  3cc
  (95%  CI)
Model  4dd
  (95%  CI)
Adipose tissue  Centimeters  −2.87  (−11.83  to  6.08)  −3.45† (−6.71  to  −0.19)  −3.54  (−8.39  to  1.30)  −0.26  (−0.95  to  0.41)
Age Years  −0.83† (−1.25  to  −0.41)  −0.80† (−1.20  to  −0.40)  −0.75† (−1.17  to  −0.33)  −0.77† (−1.19  to  −0.35)
Asthma control Controlled/partially
controlled
Baseline  Baseline  Baseline  Baseline
Uncontrolled −17.62† (−28.91  to  −0.62)  −14.52† (−25.41  to  −3.63)  −13.82† (−25.40  to  −2.24)  −17.25† (−28.28  to  −6.11)
Arterial
hypertension
No Baseline  Baseline  Baseline  Baseline
Yes 13.71† (2.85  to  24.58)  13.92† (3.36  to  24.48)  13.93† (3.19  to  24.67)  13.57† (2.73  to  24.41)
Controlled for BMI, rhinitis, use of systemic corticosteroids in one year, onset of asthma, atopy, disease duration, serum adiponectin.
† p < 0.05.
a Model 1a: Linear regression model SAT. R2: 0.355.
b Model 2b: Linear regression model VAT. R2: 0.390.
c Model 3c: Linear regression model VAT/SAT. R2: 0.370.
d Model 4d: Linear regression model WC. R2: 0.357.
Table  2  Linear  regression  model  of  pre-bronchodilator-predicted  FVC  %  in  asthmatic  women;  HUGG,  2014--2015.
FVC%  predicted
Independent  variable  Category  Model  1aa
  (95%  CI)
Model  2bb
  (95%  CI)
Model  3cc
  (95%  CI)
Model  4dd
  (95%  CI)
Adipose tissue  Centimeters  −4.07  (−12.45  to  4.30)  −3.61† (−6.65  to  −0.57)  −2.71  (−7.29  to  1.85)  −  0.37  (−1.01  to  0.26)
Age Years  −0.64† (−1.03  to  −0.24)  −0.60† (−0.97  to  −0.22)  −0.56† (−0.96  to  −0.17)  −0.56† (−0.95  to  −0.16)
Asthma control Controlled/partially
controlled
Baseline  Baseline  Baseline  Baseline
Uncontrolled −15.55† (−26.12  to  −4.99)  −12.00† (−22.15  to  −1.85)  −12.10† (−23.03  to  −1.17)  −15.03† (−25.33  to  −4.72)
Arterial
hypertension
No Baseline  Baseline  Baseline  Baseline
Yes 10.53† (0.37  to  20.69)  10.71† (0.87  to  20.55)  10.63† (0.50  to  20.76)  10.33† (0.20  to  20.45)
Controlled for BMI, rhinitis, use of systemic corticosteroids in one year, onset of asthma, atopy, disease duration, serum adiponectin. FVC (forced vital capacity) % predicted.
† p < 0.05.
a Model 1a: Linear regression model SAT. R2:0.291.
b Model 2b: Linear regression model VAT. R2: 0.335.
c Model 3c: Linear regression model VAT/SAT ratio. R2:0.296.
d Model 4d: Linear regression model WC. R2: 0.295.
Visceral  adiposity  is  associated  with  cytokines  and  lung  function  
Table  3  Linear  regression  model  of  serum  levels  of  adiponectin  a
Adiponectin  (ng/ml)  
Model    (95%  CI)  p  
BMI −0.69  (−1.19  to  −0.19)  0.007
SAT −4.08  (−7.50  to  −0.66)  0.02  













































nControlled for age, FEV1, arterial hypertension, asthma control an
VAT (visceral adipose tissue).
or  obese  according  to  BMI.  Using  WC,  WHR  and  WHtR  crite-
ria,  central  obesity  was  detected  in  75.9%,  72.3%  and  91.6%
respectively.  The  mean  of  subcutaneous  abdominal  fat  tis-
sue  (SAT)  was  2.00  ±  0.59  and  the  mean  for  the  visceral
form  was  4.57  ±  2.42  cm.  Pearson  correlation  coefﬁcients
for  BMI  with  WC  (r  =  0.78)  and  visceral  fat  (r  =  0.64)  were
better  than  those  for  the  other  measures  of  adiposity.  In
addition,  signiﬁcant  differences  in  the  level  of  asthma  con-
trol  as  a  function  of  visceral  adipose  tissue  (VAT)  and  the
VAT/SAT  ratio  were  observed.  Adiponectin  levels  were  also
associated  with  asthma  control,  as  were  age,  use  of  sys-
temic  corticosteroids,  emergency  room  visits  in  one  year,
atopy,  asthma  severity  and  pulmonary  parameters.  There
was  a  signiﬁcant  difference  between  asthma  control  and  VAT
and  the  VAT/SAT  ratio  after  adjusting  for  confounders.  The
use  of  systemic  corticosteroids  and  room  emergency  visits
in  one  year  were  also  associated  with  asthma  control  in  the
three  models  employed.  These  results  are  shown  in  tables
in  supplementary  materials.
In  linear  regression  models,  we  found  negative  associa-
tions  among  age,  TAV,  asthma  control,  FEV1 and  CVF  after
controlling  for  BMI,  rhinitis,  use  of  systemic  corticosteroids
in  one  year,  onset  of  asthma,  atopy,  disease  duration  and
serum  adiponectin  (Tables  1  and  2).
The  levels  of  adiponectin  decreased  as  a  function
of  BMI  (p-value  =  0.005),  SAT  (p-value  = 0.03)  and  VAT  (p-
value  =  0.04)  (Fig.  1),  and  IL-6  levels  were  increased,  though
not  signiﬁcantly,  as  a  function  of  TAV  (p-value  =  0.14).  To
determine  the  association  between  cytokine  levels  and  adi-
pose  tissue,  linear  models  were  ﬁtted  and  adjusted  using
previously  described  covariates.  In  a  linear  regression  model
with  adiponectin  as  the  dependent  variable,  signiﬁcant
associations  between  adiponectin  and  BMI  and  SAT  after
adjusting  for  age,  FEV1,  arterial  hypertension,  diabetes,  and
asthma  control  were  found.  However,  IL-6  was  only  asso-
ciated  with  TAV  after  adjustment  for  the  same  covariates
(Table  3).
Discussion
Our  results  show  that  VAT,  but  not  anthropometric  measures
of  central  obesity,  was  associated  with  impaired  asthma  con-
trol  after  adjusting  for  independent  variables,  including  BMI.
Although  asthma  control  and  central  obesity  have  been
shown  in  a  few  studies  to  be  associated,  these  studies
have  only  considered  anthropometric  measures  and  their
implications  are  different  views  in  relation  to  assessment
instruments  for  asthma  control.11,12 Conversely,  abdominal
subcutaneous  and  visceral  fat  deposits  in  asthmatic  patients
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nd  interleukin-6  in  asthmatic  women;  HUGG,  2014--2015.
Interleukin-6  (pg/ml)
Model    (95%  CI)  p
 0.22  (−0.13  to  0.58)  0.21
2.05  (−0.36  to  4.47)  0.09
1.20  (0.31  to  2.09)  0.009
betes. BMI (body mass index), SAT (subcutaneous adipose tissue),
Tavasoli  et  al.,25 did  not  suggest  any  association  of  WC
r  WHR  with  asthma  control,  nor  did  the  recently  published
razilian  study  by  Barros  et  al.26 In  contrast  to  our  study,
sthma  control  in  the  latter  study  was  assessed  using  a
elf-administered  questionnaire,  the  ACQ  (Asthma  Control
uestionnaire),  and  only  severe  patients  from  both  sexes
ere  included.  However,  in  a  recent  study  of  uncontrolled
sthmatic  patients,  the  authors  observed  an  association
etween  the  worst  levels  of  asthma  control  assessed  by
CT  (Asthma  Control  Test)  and  central  obesity  measures,
ndependent  of  GERD,  OSA  (obstructive  sleep  apnoea)  and
MI.27 Our  group  also  recently  reported  a  negative  associa-
ion  between  WC  and  asthma  control  in  women  assessed  by
INA  and  ACQ  but  not  with  ACT  results  after  controlling  for
ERD  and  other  variables.28 The  differences  in  these  results
ay  be  due  to  the  greater  disease  severity  as  well  as  the
se  of  the  fully  controlled  category  as  the  comparator.  In
he  current  study,  our  central  hypothesis  was  that  visceral
besity  is  associated  with  poorly  controlled  asthma,  inﬂam-
atory  cytokines  and  decreased  lung  function  in  women.
or  this  reason,  we  used  GINA  criteria,  which  are  consid-
red  to  be  the  most  recommended  asthma  assessment  tool
orldwide,  with  a  better  correlation  with  other  tools  in  rec-
gnizing  the  uncontrolled  group.29 This  present  study  also
howed  a  signiﬁcant  association  of  the  VAT/SAT  ratio  with
orse  asthma  control,  highlighting  the  possible  protective
actor  of  subcutaneous  fat.  Indeed,  Weber  et  al.  suggested
he  protective  effect  of  abdominal  and  gluteal-femoral  obe-
ity  in  a  study  in  which  they  induced  metabolic  syndrome
ith  a  high-fat  diet  in  animals  that  were  then  subjected  to
ipectomy  of  abdominal  subcutaneous  tissue.30
We  also  observed  a negative  association  of  visceral  fat
ith  the  pre-bronchodilator-  predicted  values  of  FEV1%
nd  FVC%.  To  date,  few  studies  have  evaluated  the  effect
f  abdominal  obesity  on  lung  function  or  the  relation-
hip  between  respiratory  parameters  and  abdominal  fat
eposits.  Fenger  et  al.  demonstrated  that  visceral  abdom-
nal  fat  assessed  by  ultrasound  is  associated  with  greater
eductions  in  FEV1 and  FVC  compared  with  subcutaneous  fat
nd  anthropometric  measures  of  central  obesity.23 We  also
bserved  a  borderline  negative  association  between  the
diponectin  serum  levels  and  uncontrolled  asthma.  Further-
ore,  adiponectin  was  signiﬁcantly  reduced  in  the  obese
omen  and  in  the  group  with  the  highest  subcutaneous  and
isceral  fat  deposits.  We  also  observed  that  adiponectin  was
egatively  associated  with  BMI  and  subcutaneous  fat  after
ontrolling  for  independent  variables.  In  contrast,  Holguin
t  al.  did  not  ﬁnd  any  association,  independent  of  smoking
nd  sex,  between  BMI  and  plasma  adiponectin  levels  in  21
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 negative  association,  independent  of  BMI,  of  adiponectin
ene  expression  in  VAT  of  asthmatic  obese  level  III  patients
ompared  with  levels  in  an  obese  control  group.24 We  also
bserved  higher  levels  of  IL-6  in  the  group  of  patients
ith  the  highest  percentile  of  visceral  fat  and  a  signiﬁcant
ssociation  between  IL-6  and  TAV  after  controlling  for  inde-
endent  variables.  Compared  with  abdominal  SAT,  VAT  is
onsidered  to  be  more  metabolically  active  and  can  produce
arious  hormones  and  cytokines  including  TNF- and  IL-6.6,7
owever,  few  studies  to  date  have  evaluated  cytokines
n  asthmatics.5 Sideleva  et  al.24 also  showed  higher  IL-6
xpression  in  VAT  compared  with  that  in  SAT  in  asthmatic
atients.  In  another  study,  a  positive  association  was  found
etween  IL-6  and  TNF- levels,  and  a  negative  associa-
ion  between  adiponectin  and  metabolic  syndrome  was
dentiﬁed  in  women,  which  is  similar  to  other  studies.32--34
IL-6  production  by  VAT  is  associated  with  insulin
esistance  and  metabolic  syndrome,  exhibiting  additional
ssociations  with  other  inﬂammatory  cytokines,  includ-
ng  decreased  adiponectin  levels.  Within  this  context,  we
elieve  that  the  VAT  produced  IL-6  may  inﬂuence  the  patho-
hysiology  of  asthma  in  females  and  thereby  make  it  more
ifﬁcult  to  control  asthma.  Therefore,  we  hypothesize  that
besity  in  asthmatic  patients  might  be  inﬂuenced  by  speciﬁc
nﬂammatory  cytokines  associated  with  adipose  abdominal
issue  deposits  in  a  manner  similar  to  the  chronic  inﬂam-
ation  of  adipose  tissue  that  is  observed  in  metabolic
yndrome.  We  decided  to  include  only  females  in  this  study.
n  contrast  to  men,  females  are  inﬂuenced  by  hormonal
hanges  throughout  their  entire  lives,35 and  it  is  possible
hat  these  changes  result  in  a  greater  risk  of  developing
on-atopic  asthma  and  a  worsening  of  symptoms  as  well  as
ecreased  lung  function,  and  dysregulation  of  the  immune
esponse.36,37 In  addition,  by  excluding  patients  with  level
II  obesity,  we  aimed  to  reduce  overestimation  of  asthma
ymptoms,  respiratory  function  tests  and  comorbidities  such
s  GERD  and  OSA,  which  are  directly  associated  with  obesity
nd  asthma.12,38,39 One  of  the  limitations  of  this  study  is  its
ross-sectional  design,  which  does  not  allow  determination
f  any  causal  relationship.  It  is  also  possible  that  the  study
ncluded  more  severely  affected  and  less  well-controlled
atients  than  is  typical  in  general  hospitals.
onclusion
n  conclusion,  our  results  show  a  relationship  between
isceral  obesity,  poorly  controlled  asthma  and  decreased
ung  function  in  females.  We  also  showed  that  IL-6  is  asso-
iated  with  VAT  and  that  adiponectin  with  SAT  in  asthmatic
omen.  However,  we  cannot  extrapolate  if  decreased
ulmonary  parameters  and  citokines  are  inﬂuenced  by
isceral  obesity  in  asthmatic  subjects,  since  we  didn’t
ompare  with  nonasthmatic  obese  women.  In  addition,
either  anthropometric  measures  nor  subcutaneous  adipose
bdominal  tissue  was  found  to  be  associated  with  asthma
ontrol.  We  hypothesize  that  women  should  be  studied  as  a
eparate  group  because  they  are  inﬂuenced  by  continuous
ormonal  variations  and  are  affected  by  a  more  severe
nﬂammatory  form  of  asthma.  We  suggest  studies  on  obesity
nd  asthma  be  performed  using  subjects  from  different
eographical  regions  and  various  age  groups.  We  also  thinkA.V.  Capelo  et  al.
hat  it  will  be  important  to  assess  the  adipose  tissue  in
ifferent  compartments  with  a  more  direct  or  gold  standard
easure  of  adiposity,  such  as  magnetic  resonance  imaging.
inally,  we  recommend  further  studies  with  a  control  group
f  nonasthmatic  obese  women  to  determine  if  visceral
dipose  tissue  is  negatively  associated  with  asthma  and
ncreased  inﬂammatory  markers.
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